Polyethylene glycol
As of the edition of 20 October 2026, Polyethylene glycol is a small molecule: marketed, first approved in 1987 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Cololyt
- First approved
- 17 September 1987 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- EA Pharma; 3 holders in all
- Registered trials
- 59, 5 stopped early
- Disease areas
- Digestive system; Cancer; Eye; Nervous system; Nutrition and metabolism; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 24 | 14 | 1 | 0 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 4 | 2 | 0 | 1 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 26 | 13 | 1 | 3 |
| All trials | 59 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| EA Pharma | Applicant | 2018 to now |